FDA forces troubled Advaxis to halt enrollment on its PhIII study for lead drug axalimogene
A little more than a month after Amgen quietly walked away from its $65 million upfront to partner with Advaxis $ADXS on axalimogene filolisbac …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
